RBC Capital upgraded Alcon to Outperform from Sector Perform with a price target of CHF 100, up from CHF 85. The firm cites greater confidence around the company’s medium term share gains in surgery and contact lenses, given key opinion leader feedback and upcoming launches, for the upgrade. The analyst sees further expansion of Alcon’s share of procedures in the growing surgery market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC: